CONFERENCE PROGRAM

November 15–17, 2016

JOSEPH B. MARTIN CONFERENCE CENTER • HARVARD MEDICAL SCHOOL
77 AVENUE LOUIS PASTEUR, BOSTON, MA 02115

12TH ANNUAL
PERSONALIZED
MEDICINE
CONFERENCE
Dear Colleague:

“What we need is a national conversation of experts,” Mark Levin, Partner, Third Rock Ventures, once told the audience at the Annual Personalized Medicine Conference. “Across the industry, across government, the best people in this country to come together to tell us how to maximize value for patients. That is the big challenge in our future.”

The 12th Annual Personalized Medicine Conference responds to Levin’s call to action with a concentrated focus on generating solutions to the field’s challenges. It will showcase what is new, offer insights into the issues, and provide partnership and networking opportunities for attendees. But most importantly, it will examine the unique contributions that researchers, investors, industry representatives, policy experts, payers, health care providers and patients can make at each stage in the development of personalized medicine products and services to forge a path through the field’s barriers.

The conference program, which is organized around those stages, will go beyond defining personalized medicine’s challenges by, for example:

- Exploring the latest trends in research and development
- Analyzing the issues facing the diagnostic industry
- Finding commonalities in multiple definitions of “value” in health care
- Providing examples of the kinds of evidence appropriate for coverage and payment
- Examining the best practices for integrating personalized medicine into clinical settings
- Debating the circumstances that warrant the sharing of data for research

We are pleased to present the entire conference program here, which covers these and many other topics.

Sincerely yours,

Edward Abrahams, Ph.D.
President

William S. Dalton, Ph.D., M.D.
Board Chairman
Thank You to Our Sponsors

**PLATINUM**
- Intermountain Precision Genomics
- Genentech
- Roche

**GOLD**
- astellas

**SILVER**
- Bristol-Myers Squibb
- Feinstein Kean Healthcare
- FLATIRON
- FOLEY
- ORACLE
- Pfizer
- Foundation Medicine
- Seven Bridges

**BRONZE**
- endo
- invivoscribe
- L.E.K.
- molecular health
- nanoString
- SLONE PARTNERS
- VERTEX

**CONTRIBUTOR**
- agios
- AstraZeneca
- Change Healthcare
- Genomic Health
- Greybird Ventures
- Inivata

**MEDIA PARTNERS**
- BigBio Boston
- Bio Innovation
- Genome
- genomeweb
- The Journal of Precision Medicine
Day 1 · November 15, 2016

5:30 pm  Opening Reception
Hotel Commonwealth
500 Commonwealth Avenue
Boston, MA 02215

Day 2 · November 16, 2016

7:00 am Registration and Breakfast
Joseph B. Martin Conference Center
Harvard Medical School
77 Avenue Louis Pasteur
Boston, MA 02115

8:00 am Opening Remarks
Edward Abrahams, Ph.D., President,
Personalized Medicine Coalition

8:05 am The Personalized Medicine Report
William S. Dalton, Ph.D., M.D.,
CEO, M2Gen; Director, DeBartolo Family
Personalized Medicine Institute, Moffitt
Cancer Center; Board Chairman, Personalized
Medicine Coalition

8:15 am Keynote Speaker
Greg Simon, J.D., Executive Director, Cancer
Moonshot Task Force

8:45 am Pioneering Precision: Charting a Course for
Cutting-Edge Innovations
Many scientists believe innovations in
personalized medicine are poised to yield major
breakthroughs in coming years, but not all
members of the health care system are clear on
which research topics have the most potential.
The participants in this panel will identify
the most encouraging scientific directions for
personalized medicine and point to the most
promising topics for future research.

MODERATOR | Stephen L. Eck, M.D., Ph.D.,
Vice President, Oncology Medical Sciences,
Astellas Pharma Global Development

David Altschuler, M.D., Ph.D., Executive
Vice President, Global Research, Chief
Scientific Officer, Vertex

Michael Panzara, M.D., M.P.H., Head of
Neurology Franchise, WAVE Life Sciences

Barbara Weber, M.D., Interim Chief Medical
Officer, Neon Therapeutics

9:45 am Networking Break

10:15 am Money Talks: The Future of Investment in
Personalized Medicine
Innovation requires investment. During this
discussion, a diverse panel of investors will illumi-
nate the most promising business opportunities
for advancing personalized medicine, focusing
on both macro and micro environments while
also discussing the barriers to investment and
potential solutions for removing them.

MODERATOR | Edward Winnick, Editor-in-Chief,
GenomeWeb

Alexis Borisy, Partner, Third Rock Ventures
Vamil Divan, M.D., M.B.A., Senior Research
Analyst, Credit Suisse
Ryan Lindquist, M.B.A., Director, Investment
Banking, Leerink Partners

11:15 am You + 999,999: How a 1 Million-Person Cohort
Can Pave the Way for Personalized Care

INTRODUCTION | Paolo Narvaez, Ph.D., Senior
Principal Engineer, Director of Engineering,
Intel Corporation

KEYNOTE | Eric Dishman, Director, All of Us
Research Program, National Institutes of Health

12:00 pm Luncheon
1:15 pm  **Update: Kraft Precision Medicine Accelerator & Trials Challenge Award**

An update on the activities of the Kraft Precision Medicine Accelerator and interviews with the winners of Harvard Business School’s “Precision Trials Challenge,” sponsored by Kraft Precision Medicine Accelerator.

**PRESENTER** | Richard Hamermesh, D.B.A., Faculty Co-Chair, Kraft Precision Medicine Accelerator, Harvard Business School

**WINNER** | MatchMiner
Team Lead: Ethan Cerami, Ph.D., Director, Knowledge Systems Group, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute

**RUNNER UP** | No Patients Left Behind
Team Lead: Gavin MacBeath, Ph.D., Founder, SAB Member, Merrimack Pharmaceuticals

**RUNNER UP** | iCare for Cancer Patients
Team Lead: Leylah Drusbosky, Ph.D., Scientific Director, iCare for Cancer Patients, Assistant Professor of Medicine, University of Florida

1:45 pm  **Reforming Clinical Trials: How Alternative Trial Designs May Reshape Regulatory Review**

Traditional clinical trial designs are often too cumbersome and expensive to study the efficacy of personalized medicine products and services in sub-populations of patients. Yet there is no consensus on which methods have the most promise to speed trials and lower costs. During her keynote address, Dr. Woodcock will describe the progressive designs she believes are best suited to demonstrate the efficacy of personalized medicine based on past successes and proposed reforms.

**INTRODUCTION** | Bonnie J. Addario, Founder, Chair, Bonnie J. Addario Lung Cancer Foundation; Founder, Addario Lung Cancer Medical Institute

**KEYNOTE** | Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA

2:15 pm  **Fireside Chat**

**MODERATOR** | Alexander Vadas, Ph.D., Managing Director, Partner, L.E.K. Consulting

**KEYNOTE** | Peer M. Schatz, M.B.A., CEO, QIAGEN

2:45 pm  **Networking Break**

3:15 pm  **Diagnostics Debate: Regulatory and Reimbursement Hurdles for Personalized Medicine Diagnostics**

Nowhere are the regulatory and reimbursement challenges facing personalized medicine more evident than in the diagnostics industry, where the routes to market are often hampered by a lack of clarity regarding the possible changes to the regulatory pathway for laboratory-developed tests, ambiguity regarding the kinds of evidence that justify payment, and the need for large marketing budgets to sell low-cost procedures, all of which impede the development of sophisticated diagnostics with the power to transform medicine. During this panel discussion, representatives from a diverse range of diagnostic companies, a payer and FDA will identify the most promising strategies to alter the landscape to encourage investment in personalized medicine diagnostic products, including the roles of other stakeholders such as the pharmaceutical industry and integrated health systems.

**MODERATOR** | Ronnie Andrews, Founder, Principal, The Bethesda Group

Suzanne Belinson, Ph.D., M.P.H., Executive Director, Center for Clinical Effectiveness, Blue Cross Blue Shield Association

Brad Gray, CEO, President, NanoString Technologies

Elizabeth Mansfield, Ph.D., Deputy Office Director, Personalized Medicine and Molecular Genetics, Office of In Vitro Diagnostics and Radiological Health, CDRH, FDA

Michael J. Pellini, M.D., CEO, Foundation Medicine
4:30 pm  Visions of Value: Evaluating Evidence for Personalized Medicine

The fact that payers, providers, patients, industry representatives and regulators all define value differently makes it difficult for personalized medicine’s champions to contribute to and communicate about the body of evidence supporting the field. Participants in this panel discussion will bring the personalized medicine community closer to an accepted definition of value by identifying common elements in multiple definitions of the concept.

MODERATOR | Susan Dentzer, President, CEO, Network for Excellence in Health Innovation

Peter B. Bach, M.D., M.A.P.P., Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Donna Cryer, J.D., President, CEO, Global Liver Institute

Lori M. Reilly, J.D., Executive Vice President, Policy & Research, PhRMA

Michael S. Sherman, M.D., M.B.A., Senior Vice President, Chief Medical Officer, Harvard Pilgrim Health Care

5:30 pm  Elements Café Cocktail Reception

8:45 am  Coverage is King: Identifying the Evidence That Leads to Reimbursement

Many innovators in personalized medicine are unclear on the kinds of evidence that inform the coverage and payment decisions of payers. That lack of clarity can have negative financial consequences for personalized medicine companies with products and services that are on the market but not paid for. During this panel, payer representatives will help define the reimbursement landscape for the field by providing examples of the evidence they consider appropriate for coverage and payment.

MODERATOR | Amy M. Miller, Ph.D., Executive Vice President, Personalized Medicine Coalition

Kristine Bordenave, M.D., F.A.C.P., Lead Medical Director, Humana

Matthew Fontana, M.D., Vice President, Chief Medical Officer, Pharmacy, Health Care Service Corporation

Elaine Jeter, M.D., MolDx Medical Director, Palmetto GBA

9:45 am  Networking Break

10:15 am  HBS Case Presentation

The CRISPR-Cas9 technology has the potential to deliver precision medicine in its most basic form by allowing precise gene editing. The technique could possibly be used to cure many of the most intractable of diseases and has enormous scientific and commercial potential. Currently, the intellectual property rights to the CRISPR-Cas9 technology are the subject of a patent dispute between the Broad Institute and the University of California Berkeley. Our discussion of the case will focus on the implications of the technology and the current litigation on the advancement of efficacious treatments reaching patients faster. In addition, we will discuss the ethical issues of extending gene editing beyond curative uses to the alteration of human traits. The case presents a balanced view of this full range of issues and is intended to stimulate a serious and engaging discussion. (cont. on next page)
LEADER | Richard Hamermesh, D.B.A., Senior Fellow, Former MBA Class of 1961, Professor of Management Practice, Harvard Business School

11:15 am   Keynote Speaker

INTRODUCTION | William Chin, M.D., Chief Medical Officer, Executive Vice President, Science & Regulatory Advocacy, PhRMA

KEYNOTE | Victor Dzau, M.D., President, National Academy of Medicine

11:45 am   Bag Lunch

12:45 pm   Personalizing Care: Strategies for Integrating Personalized Medicine into Health Care

Personalized medicine lacks sufficient literature on how health care providers can integrate personalized medicine into clinical care, which makes it difficult for providers to take advantage of the growing number of personalized medicine products and services now available to them. During this session, panelists who have spearheaded integration efforts will share the strategies they found most useful for speeding the pace of personalized medicine’s adoption in clinical settings.

MODERATOR | Howard McLeod, Pharm.D., Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center

Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

Dax Kurbegov, M.D., Vice President, Institute for Research and Innovation, Catholic Health Initiatives

Lincoln Nadauld, M.D., Ph.D., Executive Director, Precision Medicine and Precision Genomics, Intermountain Healthcare

Peter H. O’Donnell, M.D., Assistant Professor of Medicine, Associate Director for Clinical Implementation, Center for Personalized Therapeutics, The University of Chicago

1:45 pm   Leadership in Personalized Medicine Award

PRESENTER | William S. Dalton, Ph.D., M.D., CEO, M2Gen; Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center; Board Chairman, Personalized Medicine Coalition

RECIPIENT | Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School

2:15 pm   Networking Break

2:45 pm   The Data Dilemma: Fulfilling Expectations of Big Data in the Future of Personalized Medicine

There is consensus that the massive amounts of genomic, clinical, claims and other types of data could yield important insights for research and clinical care. But for years, obstacles around technical standards, interoperability, privacy and confidentiality, data security, and consent have been held up as daunting challenges that inevitably slowed progress. During this discussion, a panel of academic and industry experts will discuss their respective organizations’ strategies to obtain and analyze the data, including what has worked and what has not; the programs and processes that have led to the most productive data usage; examples of important knowledge that has been derived from data analysis; and the infrastructure they believe is needed to achieve fulfillment of the potential of big data in personalized medicine nationwide.

MODERATOR | Marcia A. Kean, M.B.A., Chairman, Strategic Initiatives, Feinstein Kean Healthcare

Paul Bleicher, M.D., Ph.D., CEO, OptumLabs

Christophe G. Lambert, Ph.D., Associate Professor of Medicine, Center for Global Health, Division of Translational Informatics, Department of Internal Medicine, University of New Mexico

Adam Margolin, Ph.D., Director, Computational Biology, Associate Professor, Oregon Health & Science University

Edward Stepanski, Ph.D., Chief Operating Officer, Vector Oncology
3:45 pm  **Medicine and the Targeted Marketing Problem**

We live in the golden age of cloud computing and machine learning. The organizing conundrum for the “big data era,” however, is a surprising one — the “targeted marketing problem” (i.e., the ability to better match the right customers to targeted messages). This talk will explore overlaps and similarities between the targeted marketing problem and precision medicine, and how advances in data sciences can be leveraged to create a learning medical system that in turn points to the health care system of the future.

**INTRODUCTION | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health**

**KEYNOTE | Anthony Philippakis, M.D., Ph.D., Chief Data Officer, Broad Institute; Venture Partner, GV**

4:30 pm  **Closing Remarks**

Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
“What we need is a national conversation of experts. Across the industry, across government, the best people in this country to come together to tell us how to maximize value for patients. That is the big challenge in our future.”

— Mark Levin, Partner, Third Rock Ventures
Speakers

Amy Abernethy, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

Amy P. Abernethy, M.D., Ph.D., is the Chief Medical Officer and Chief Scientific Officer at Flatiron Health, a health care technology company focused on accelerating research and dramatically improving treatment for people with cancer. She is a hematologist/oncologist and palliative medicine physician, and an internationally recognized cancer clinical researcher with more than 400 publications.

Dr. Abernethy is an appointee to the National Academy of Medicine’s (formerly the Institute of Medicine) National Cancer Policy Forum, serves on the Executive Board for the Personalized Medicine Coalition, and is a former President of the American Academy of Hospice & Palliative Medicine. Before joining Flatiron, Dr. Abernethy was a Professor of Medicine at Duke University School of Medicine. She ran the Center for Learning Health Care in the Duke Clinical Research Institute and the Duke Cancer Care Research Program in the Duke Cancer Institute. She is also on the Board of Directors of athenahealth, Inc. and was featured on TEDMED in 2013.

Edward Abrahams, Ph.D.
President, Personalized Medicine Coalition

Edward Abrahams, Ph.D., is President of the Personalized Medicine Coalition. Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.

Previously, Dr. Abrahams was Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier, he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.

Dr. Abrahams worked for seven years for the U.S. Congress, including as a Legislative Assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for Representative Edward J. Markey.

The author of numerous essays, Dr. Abrahams now serves on the Editorial Board of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.
Bonnie J. Addario
Founder, Chair, Bonnie J. Addario Lung Cancer Foundation; Founder, Addario Lung Cancer Medical Institute

Bonnie Addario, Founder, Chair and lung cancer survivor, has been an activist, advocate, educator and change agent empowering patients and giving them a strong voice in the fight against lung cancer since receiving a stage 3B diagnosis more than a decade ago. Although thrust into a role that she had never envisioned for herself, she embraced it and now considers it to be her second career and a personal calling. Recognizing the critical need for education, empowerment, advocacy and research to help patients and families, especially those without resources and support, Bonnie and her family founded the Bonnie J. Addario Lung Cancer Foundation (ALCF) in 2006, and then went on to found the Addario Lung Cancer Medical Institute (ALCMI) with her husband, Tony Addario, in 2008. Bonnie’s business acumen and skills, honed in her first career as President of Olympian Oil Company and Commercial Fueling Network (CFN), as past President of the CA Independent Oil Marketers Association (CIOMA) and as a community activist serving on diverse boards, have all contributed to her work at ALCF in developing business strategies and being the Foundation’s patient voice at national and international conferences, on panels and boards, and to industry leaders, clinicians and policy makers.

David Altshuler, M.D., Ph.D.
Executive Vice President, Global Research, Chief Scientific Officer, Vertex

David Altshuler is Executive Vice President, Global Research, and Chief Scientific Officer at Vertex Pharmaceuticals. Dr. Altshuler leads Vertex’s research efforts aimed at discovering new medicines for the treatment of serious diseases and oversees the company’s five research sites in the United States, Canada and Europe.

David was previously one of four founding members, Deputy Director and Chief Academic Officer, at the Broad Institute of Harvard and MIT, a professor at Harvard and MIT, and a physician at Massachusetts General Hospital. He was a leader of the SNP Consortium, HapMap and 1,000 Genome Projects, and discovered over 100 gene variants associated with type 2 diabetes and other common diseases. A member of the National Academy of Medicine (formerly the Institute of Medicine) and the American Academy of Arts and Sciences, David was named a Champion of Change by the White House for his leadership in creating and leading the Global Alliance for Genomics and Health.
Ronnie Andrews  
**Founder, Principal, The Bethesda Group**

Mr. Andrews is the Founder and Principal of The Bethesda Group and has nearly 30 years of experience in the clinical and molecular diagnostics industry. He previously served as the President of the Genetic Science Division for Thermo Fisher Scientific, overseeing the integration of Life Technologies’ genetic platforms, including Life’s chip-based next-generation sequencing technology, Ion Torrent. Prior to Life Technologies, Mr. Andrews worked as President of the Medical Sciences Venture within the Life Technologies Corporation and as the Chief Executive Officer of Clarient, Inc. He also previously held various senior executive roles at Roche Molecular Diagnostics and Roche Diagnostics Corporation, where he oversaw the effort to transition HIV viral load testing and viral genotyping into a collaborative effort with pharma to capture resistance data allowing for earlier detection of potential therapeutic failure. The diagnostics modality learned during these critical years of HIV management evolution have been invaluable as we take on cancer. Throughout his career, Mr. Andrews has raised over $100 million in private and public funds, and was selected as the Regional Winner for Ernst & Young’s Entrepreneur of the Year in 2011.

Peter B. Bach, M.D., M.A.P.P.  
**Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center**

The Director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes, Dr. Bach is a physician, epidemiologist, researcher and recognized health care policy expert whose recent work focuses on the high cost of prescription drugs and pricing structures. Dr. Bach is leading efforts to increase understanding of the U.S. drug development process and develop new models for drug pricing that include patient value as a critical component.

He serves on the Board of Advisors of the University of Michigan Cancer Center; on the World Economic Forum; and is a member of the Clinton Global Initiative. He is also a member of the National Academy of Medicine (formerly Institute of Medicine)’s Board on Health Care Services, the National Cancer Policy Forum and the Committee on Performance Measurement of the National Committee on Quality Assurance.

Dr. Bach earned a B.A. from Harvard University and completed his medical studies at the University of Minnesota and the University of Chicago Harris School. He received his internal medicine training from Johns Hopkins University and completed a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins.
Suzanne Belinson, Ph.D., M.P.H.
Executive Director, Center for Clinical Effectiveness, Blue Cross Blue Shield Association

Suzanne Belinson is the Executive Director of the Center for Clinical Effectiveness at the Blue Cross Blue Shield Association (BCBSA), a national federation of 36 independent community-based and locally operated Blue Cross and Blue Shield companies. The Blue system is the nation’s largest health insurer, covering over 100 million — one-in-three Americans. As the Executive Director for the Center for Clinical Effectiveness, Dr. Belinson leads the operational and financial responsibilities of the center. In addition, as part of the leadership team in the Office of Clinical Affairs, she focuses on the development of emerging programs and services that enhance clinical effectiveness for the independent BCBS plans.

Before joining BCBSA, Dr. Belinson served as an NIH Clinical Cancer Fellow at Northwestern University, where her work focused on community-based interventions. Dr. Belinson developed and tested community-based models for cervical cancer screening with both domestic and international applications. Dr. Belinson continues to serve as adjunct faculty at Northwestern University.

Dr. Belinson received her bachelor’s degree from Cleveland State University and a Ph.D. in epidemiology from the University of North Carolina at Chapel Hill. She also holds a master’s in public health from the University of Pittsburgh.

Paul Bleicher, M.D., Ph.D.
CEO, OptumLabs

Paul Bleicher is the CEO of OptumLabs, an open, collaborative research and innovation center aimed at accelerating improvements in patient care and value through clinical, policy and product innovation driven by new insights from big data. He previously worked as Chief Medical Officer for Humedica, a next-generation clinical informatics company, where he built and managed the company’s analytic operations. He also founded and served as CEO of Phase Forward, a company that developed web-based electronic data capture for clinical trials, until its 2010 acquisition by Oracle Corporation.

Dr. Bleicher is currently a member of the National Academy of Medicine (formerly the Institute of Medicine)’s Leadership Consortium for Value & Science-Driven Health Care, and also serves on the Editorial Board of Therapeutic Innovation and Regulatory Science.

Dr. Bleicher earned his B.S. from Rensselaer Polytechnic Institute, and his M.D. and Ph.D. from the University of Rochester School of Medicine and Dentistry, specializing in cellular immunology. He trained in internal medicine at the Beth Israel Hospital and dermatology at Harvard Medical School/Massachusetts General Hospital. He completed a post-doctoral fellowship at the Dana-Farber Cancer Institute in molecular biology.
Kristine Bordenave, M.D., F.A.C.P.
Lead Medical Director, Humana

Dr. Kristine Bordenave is the Lead Medical Director for Humana’s claims cost management division, which ensures efficient, high-quality resources supporting positive clinical outcomes for present and future generations. She has a strong background in Medicare and Medicaid regulation, fraud/waste/abuse, coding, tailored quality improvement, and innovative health care delivery system redesign. An internist, she received her medical degree from the University of New Mexico School of Medicine, with additional training through the American College of Physician Executives.

Alexis Borisy
Partner, Third Rock Ventures

Alexis Borisy is a successful biotechnology entrepreneur with more than 20 years of experience building and operating innovative science-based organizations. Alexis joined Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies. He has played key roles in launching and building several companies including Foundation Medicine, Warp Drive Bio, Blueprint Medicines, Editas Medicine and Revolution Medicine.

Prior to joining Third Rock Ventures, Alexis founded CombinatoRx in 2000, serving as its Chief Executive Officer and bringing the company public on the NASDAQ. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Alexis was honored as the Massachusetts Institute of Technology’s Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a Presidential Scholar.

Alexis has an undergraduate degree in chemistry from the University of Chicago, and also did graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University. Alexis is a trustee of the Boston Museum of Science, is a co-Founder and former Chairman of FORMA Therapeutics, and serves on the Board of the National Venture Capital Association.
Ethan Cerami, Ph.D.
Director, Knowledge Systems Group, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute

Ethan Cerami, Ph.D. is the Director of the Knowledge Systems Group at the cBio Center and Lead Scientist in the Department of Biostatistics and Computational Biology at Dana-Farber Cancer Institute. Prior to joining Dana-Farber, Ethan was the Director of Computational Biology at Blueprint Medicine, and Director of Cancer Informatics Development at Memorial Sloan Kettering Cancer Center (MSKCC). While at MSKCC, Ethan co-founded the cBioPortal for Cancer Genomics, and his group remains active in its continued development.

William Chin, M.D.
Chief Medical Officer, Executive Vice President, Science & Regulatory Advocacy, PhRMA

Dr. William W. Chin is the Executive Vice President for Science and Regulatory Advocacy and Chief Medical Officer at PhRMA where he leads PhRMA’s continuing efforts in science and regulatory advocacy in the drug discovery and development ecosystem. He was the Executive Dean for Research, Bertarelli Professor of Translational Medical Science and Professor of Medicine at Harvard Medical School (HMS). In this role, Dr. Chin spearheaded efforts to design and implement the vision for research at HMS, with special emphasis on interdisciplinary and translational research that crosses departmental and institutional boundaries.

Chin is a Harvard-trained endocrinologist and long-standing faculty member. During his tenure as a faculty member in the Department of Medicine at Brigham and Women’s Hospital, he became Chief of the Genetics Division and a Howard Hughes Medical Institute investigator, advancing to Professor of Medicine, and Obstetrics, Gynecology and Reproductive Biology at HMS. Prior to HMS, Dr. Chin was at Eli Lilly and Company, where he had worked for the last decade, most recently as Senior Vice President for Discovery Research and Clinical Investigation. He received his A.B. from Columbia University and his M.D. from Harvard Medical School.
Donna Cryer, J.D.
President, CEO, Global Liver Institute

Donna R. Cryer has channeled her personal experience as an IBD and liver transplant patient into professional advocacy as President and Chief Executive Officer of the Global Liver Institute.

Ms. Cryer brings the patient voice into policy and research deliberations through service to FDA, PCORI, ONC and NIH. Additionally, Ms. Cryer serves on the Gastroenterology Board of the ABIM and the Personalized Medicine Coalition and is Chair of the Society for Participatory Medicine.

William S. Dalton, Ph.D., M.D.
CEO, M2Gen; Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center; Board Chairman, Personalized Medicine Coalition

Dr. William “Bill” S. Dalton is Founder and CEO of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. He is the past President, CEO & Center Director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002-2012). Prior to his role as the President, CEO & Center Director of Moffitt Cancer Center, Dr. Dalton was the Dean of the University of Arizona College of Medicine.

Dr. Dalton is interested in the development of personalized cancer care and patient-centered outcomes research through Moffitt’s nationally renowned Total Cancer Care™ approach to developing evidence-based, personalized cancer treatments and information / decision tools for patients and clinicians. Total Cancer Care includes one of the largest cancer tumor bio-repositories and data warehouses in the U.S. dedicated to the development of personalized medicine. He is also recognized as a founder of ORIEN, an alliance of cancer centers which have agreed to use the Total Cancer Care protocol to generate and share data for collaborative research and learning. For his leadership in this area, Dr. Dalton was recognized as the 2010 recipient of the Personalized Medicine Coalition’s Leadership in Personalized Medicine Award. Dr. Dalton’s basic and translational research interests focus on molecular mechanisms of drug resistance and drug discovery. He has over 200 publications, serves on several editorial boards and has numerous patents in the fields of drug discovery and personalized medicine.
Susan Dentzer
President, CEO, Network for Excellence in Health Innovation

Susan Dentzer is President and Chief Executive Officer of the Network for Excellence in Health Innovation, a nonprofit think tank whose supporting members span the spectrum of health care. NEHI produces research and policy recommendations in pursuit of the "Triple Aim:" achieving better health, better care and more sustainable health spending for the nation.

Previously, Dentzer served as Senior Policy Adviser to the Robert Wood Johnson Foundation, the nation’s largest philanthropy focused on U.S. health and health care; was Editor-in-Chief of the journal Health Affairs; and served as On-Air Correspondent on health issues for PBS NewsHour. She is an elected member of the National Academy of Medicine (formerly the Institute of Medicine) and the Council on Foreign Relations. She is a Fellow of the National Academy of Social Insurance and of the Hastings Center. She also serves on the Board of Directors of the International Rescue Committee, Research!America, the American Board of Medical Specialties and the Public Health Institute.

Dentzer is a graduate and trustee emerita of Dartmouth and formerly chaired the Dartmouth Board of Trustees. She also serves on the Board of Overseers of the Geisel School of Medicine at Dartmouth. She was also a Nieman Fellow at Harvard University from 1986–1987.

Eric Dishman
Director, All of Us Research Program, National Institutes of Health

Eric Dishman is the Director of the All of Us Research Program at NIH. In this role, he leads efforts to build a research cohort of one million U.S. participants to advance precision medicine.

Previously, Eric was an Intel Fellow and Vice President of the Health and Life Sciences Group at Intel Corporation, where he was responsible for driving Intel’s cross-business strategy, research and development, and product and policy initiatives for health and life science solutions.

He is widely recognized as a global leader in health care innovation, with specific expertise in home and community-based technologies and services for chronic disease management and independent living. Trained as a social scientist, Dishman is known for pioneering innovation techniques that incorporate anthropology, ethnography and other social science methods into the development of new technologies. He also brings his own experience as a cancer patient for 23 years — finally cured thanks to precision medicine — to drive a person-centric view of health care transformation.
Vamil Divan, M.D., M.B.A.
Senior Research Analyst, Credit Suisse

Vamil Divan has worked in equity research at Credit Suisse since 2007 and is now the Senior Analyst covering the U.S. pharmaceutical sector. From 2011-2013 he led the Life Science Tools and Diagnostics Team and prior to that he was a member of the U.S. Pharmaceuticals Team. Before joining Credit Suisse, Vamil worked in the pharmaceutical industry for five years (at Roche and then Pfizer) and before that was a practicing physician. Vamil holds an M.D. from the University of Buffalo and an M.B.A. from New York University.

Leylah Drusbosky, Ph.D.
Scientific Director, iCare for Cancer Patients, Assistant Professor of Medicine, University of Florida

Leylah Drusbosky, Ph.D., is an Assistant Professor of Medicine and the Scientific Director of iCare for Cancer Patients, a precision oncology program at the University of Florida. The iCare program analyzes next generation sequencing, cytogenetics, FISH and chromosomal copy number variations using a new computational biology method to predict a patient’s response to standard of care therapy, and recommend combinations of FDA approved drugs predicted to possess antineoplastic activity. Prior to directing iCare scientific efforts, Dr. Drusbosky discovered a novel adhesion molecule axis that protects leukemia cells from chemotherapy. This work led to a high throughput assay used to identify newly patented drug classes and a Phase I/II clinical trial in patients with relapse and refractory leukemia. Dr. Drusbosky is also a founding member of CancerPOP, a public-accessible precision oncology program for people with cancer who have failed guideline directed treatment and are in search of new therapeutic options.
Victor Dzau, M.D.
President, National Academy of Medicine

Victor J. Dzau is the President of the National Academy of Medicine (NAM) formerly the Institute of Medicine (IOM). In addition, he serves as Chair of the Health and Medicine Division Committee of the National Academies of Sciences, Engineering, and Medicine, and Vice Chair of the National Research Council. Dr. Dzau is Chancellor Emeritus and James B. Duke Professor of Medicine at Duke University and the past President and CEO of the Duke University Health System. Previously, Dr. Dzau was the Hersey Professor of Theory and Practice of Medicine and Chairman of Medicine at Harvard Medical School’s Brigham and Women’s Hospital, as well as Chairman of the Department of Medicine at Stanford University.

Dr. Dzau advises governments, corporations and universities worldwide, previously serving as a member of the Advisory Committee to the Director of the National Institutes of Health (NIH) and as Chair of the NIH Cardiovascular Disease Advisory Committee. Currently, he is a member of the Board of the Singapore Health System and Hamad Medical Corporation, Qatar. He was on the Board of Health Governors of the World Economic Forum and chaired its Global Agenda Council on Personalized and Precision Medicine.

Stephen L. Eck, M.D., Ph.D.
Vice President, Oncology Medical Sciences, Astellas Pharma Global Development

Dr. Eck is Vice President, Oncology Medical Sciences at Astellas, where he is responsible for the design and conduct of oncology studies in all phases of clinical development. Dr. Eck previously served as Vice President, Translational Medicine & Pharmacogenomics, at Eli Lilly, where he was responsible for the clinical pharmacology components of drug development including both early-phase clinical studies and late-stage drug development studies. Dr. Eck also previously served in a variety of drug development leadership roles at Pfizer.

Dr. Eck is a hematologist/oncologist with broad drug development experience in oncology and neuroscience and is a Fellow of the American Association for the Advancement of Science (pharmacology). He serves on the Board of Directors of Luminex Corporation, on the Scientific Advisory Board of the ACGT Foundation, on the Board of Trustees of the Keck Graduate School, on the Board of Directors of the Central Pennsylvania Clinic, a non-profit health care organization for children and adults with rare genetic diseases, and on the Board of Directors of the Personalized Medicine Coalition, a non-profit education and advocacy organization.
Dr. Matthew Fontana is the Vice President and Chief Medical Officer of Pharmacy at Health Care Service Corporation (HSCS), where he manages the design and execution of HCSC pharmacy benefits and programs. In this role, he leads a team of pharmacists, clinicians and other health care specialists in developing tools and relationships that enable pharmacotherapeutics and pharmacy-related services to be delivered at lower costs and with enhanced quality. Dr. Fontana received his bachelor’s degree from Harvard University, where his course of study was concentrated in biology and molecular evolution. He attended the Medical College of Pennsylvania and completed his internal medicine residency at the University of Texas Health Science Center at San Antonio. He is a diplomate of the American Board of Internal Medicine and serves as an elected officer of the New Mexico Medical Society. Dr. Fontana joined HCSC in 2008 as the Chief Medical Officer for Blue Cross Blue Shield of New Mexico before assuming his current role in 2011.

R. Bradley Gray is the President and CEO of NanoString Technologies and has served as a member of the Board of Directors since 2010. Prior to joining NanoString, Mr. Gray served as Vice President of Product and Business Development for Genzyme Genetics, the diagnostic services division of Genzyme, leading the development of molecular diagnostics and partnering activities. Previously, he served as Vice President of Business and Strategic Development for Genzyme Genetics, leading growth efforts through partnerships and licensing, and as Director of Corporate Development, supporting business development and leading Genzyme Ventures, the corporate venture capital fund of Genzyme. Prior to joining Genzyme, Mr. Gray was a management consultant in the health care practice of McKinsey & Company, a global management consulting firm, from September 2000 to October 2004, where he worked with senior health care executives in the United States and Europe on a broad range of issues including pharmaceutical and diagnostic product strategy, post-merger integration, organizational design and operational turnarounds. Mr. Gray received a B.A. in economics and management from Oxford University, where he studied as a British Marshall Scholar, and an S.B. in chemical engineering from the Massachusetts Institute of Technology.
Richard Hamermesh, D.B.A.
Faculty Co-Chair, Kraft Precision Medicine Accelerator, Senior Fellow, Former MBA Class of 1961, Professor of Management Practice, Harvard Business School

Richard Hamermesh is a Senior Fellow at the Harvard Business School where he was formerly the MBA Class of 1961 Professor of Management Practice. Richard created and teaches the second-year M.B.A. elective, Building Life Science Businesses. Richard was the founding Faculty Chair of the HBS Healthcare Initiative and is the faculty co-chair of the HBS/Kraft Precision Medicine Accelerator. From 1987 to 2001, Richard was a co-founder and a Managing Partner of The Center for Executive Development, an executive education and development consulting firm.

Richard is also an active investor and entrepreneur, having participated as a principal, director and investor in the founding and early stages of more than 20 organizations. He was the founding president of the Newton (MA) Schools Foundation and served on the editorial board of the Harvard Business Review.

Elaine Jeter, M.D.
MolDx Medical Director, Palmetto GBA

Elaine K. Jeter, M.D. is a Palmetto GBA Medical Director in JM and Director of the Molecular Diagnostic (MolDX) project. She is a graduate of the Medical University of South Carolina (MUSC) and is Board-certified in clinical and anatomic pathology, with subspecialty Boards in blood banking/transfusion medicine. She has practiced pathology and laboratory medicine in the private and academic setting, and has been with Palmetto GBA for nearly 12 years.
Marcia A. Kean, M.B.A.
Chairman, Strategic Initiatives, Feinstein Kean Healthcare

Marcia A. Kean is Chairman, Strategic Initiatives, of Feinstein Kean Healthcare, a leading strategy and communications firm dedicated to advancing innovation in the life sciences and health care. For more than three decades, Marcia has consistently identified and helped drive adoption of new waves of technology that have transformative impact on health care.

Marcia led communications for the National Cancer Institute’s first-generation data exchange and bioinformatics program for seven years. She served as co-Vice Chair of the Advisory Committee of the Institute of Medicine’s Cancer Informatics Workshop in 2012. She founded and chairs the Advisory Committee of the “Turning the Tide Against Cancer Through Sustained Medical Innovation,” a national initiative on policy co-convened by the Personalized Medicine Coalition, American Association for Cancer Research and Feinstein Kean Healthcare. She leads Feinstein Kean’s partnership in iConquerMS™, a novel patient-powered research initiative to accelerate multiple sclerosis research with an online data collection and analysis platform. Marcia holds an M.B.A. from New York University and a B.A. from the University of California at Berkeley.

Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics,
Harvard Medical School

Raju Kucherlapati, Ph.D., is the Paul C. Cabot Professor in the Harvard Medical School Department of Genetics. He is also a professor in the Department of Medicine at Brigham and Women’s Hospital. Dr. Kucherlapati was the first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics. His research focuses on gene mapping, gene modification and cloning disease genes. During 1989-2001, Dr. Kucherlapati was the Lola and Saul Kramer Professor of Molecular Genetics and Chairman of the Department of Molecular Genetics at the Albert Einstein College of Medicine in New York. He was previously a professor in the Department of Genetics at the University of Illinois, College of Medicine. He began his research as an assistant professor in the Department of Biochemical Sciences at Princeton University.

He has chaired numerous NIH committees and served on the National Advisory Council for Human Genome Research and the NCI Mouse Models for Human Cancer Consortium. He is also a member of the Cancer Genome Atlas project of NIH. He is a member of the National Academy of Medicine and a Fellow of the American Association for the Advancement of Science.

Dr. Kucherlapati received his B.S. and M.S. in biology from universities in India, and he received his Ph.D. from the University of Illinois at Urbana. He conducted post-doctoral work at Yale University.
Dax Kurbegov, M.D.
Vice President, Institute for Research and Innovation, Catholic Health Initiatives

Dr. Kurbegov is Vice President of the Catholic Health Initiatives (CHI) Institute for Research and Innovation (CIRI). He assumed leadership in June of 2016 after joining CHI in 2012 as Physician Vice-President of the National Oncology Service Line, serving as the voice of cancer care practitioners within the organization. In his current role, Dr. Kurbegov leads a team dedicated to advancing research in the community setting, reducing research related risk across CHI’s 103 hospitals and pioneering CHI’s data science capabilities.

Complementing his research efforts, Dr. Kurbegov also serves as Physician Leader of CHI’s precision medicine program, which seeks to empower care providers to appropriately utilize emerging technologies to optimize the care of individual patients.

In addition, Dr. Kurbegov serves as Principal Investigator for CHI’s Oncology Research Alliance, selected in 2014 as one of 34 recipients of the NCI Community Oncology Research Program (NCORP) award. He is Chair-elect of the ASCO Research Community Forum and serves on the ASCO Cancer Research Committee. Dr. Kurbegov is an Adjunct Assistant Professor in the Baylor College of Medicine Voluntary Faculty. Dr. Kurbegov received his B.S. in biological sciences at Stanford University, received his doctorate at Baylor College of Medicine and completed his oncology training at the MD Anderson Cancer Center.

Christophe G. Lambert, Ph.D.
Associate Professor of Medicine, Center for Global Health, Division of Translational Informatics, Department of Internal Medicine, University of New Mexico

Christophe G. Lambert, Ph.D., is an Associate Professor of Medicine at the University of New Mexico, with appointments in the Center for Global Health and the Division of Translational Informatics within the Department of Internal Medicine. He is a member of the Observational Health Data Sciences and Informatics (OHDSI) Collaborative, and serves as co-Chair of the Oncology Research Information Exchange Network (ORIEN) Informatics Workgroup. He is also the founder, past CEO and current Chairman of Golden Helix, a bioinformatics company whose software has been cited in over 1000 peer-reviewed publications over the past 18 years.

Dr. Lambert’s current research is in: (1) methods to derive high-quality evidence from large-scale patient medical records; (2) longitudinal comparative effectiveness of bipolar disorder therapies using large-scale observational data; and (3) the genetics of pediatric diseases. Throughout his career, he has been an advocate and exemplar of applying systems thinking to the challenging problems affecting health care and health care research, with numerous articles and presentations diagnosing systemic problems and prescribing the change management required for improvement. Dr. Lambert received his bachelor’s degree from Montana State University, and a Ph.D. in computer science from Duke University.
Ryan Lindquist, M.B.A.
Director, Investment Banking, Leerink Partners

Ryan Lindquist is a Director at Leerink Partners, a leading investment bank focused exclusively on Healthcare, where he helps to lead the firm’s Medical Devices, Diagnostics and Life Science Tools practice. Ryan joined Leerink in 2009 from Merrill Lynch’s Global Healthcare Group where he spent his time working with clients across the Healthcare industry. Prior to joining Merrill Lynch in 2005, he was a consultant at Deloitte. Over the course of his career, Ryan has advised clients on over 50 M&A advisory assignments and debt, equity and equity-linked financings.

Ryan earned his M.B.A. with high honors from The University of Chicago and his B.A. in Economics from Lehigh University.

Gavin MacBeath, Ph.D.
Founder, SAB Member, Merrimack Pharmaceuticals

Gavin MacBeath, Ph.D., is a founder of Merrimack Pharmaceuticals, where he currently serves on the Scientific Advisory Board, and a founder of Chestnut Pharmaceuticals, where he serves on the Board of Directors. Previously, Dr. MacBeath served as SVP of Discovery and Head of Translational Medicine at Merrimack from 2010 to 2016, and as Lecturer and PI in the Department of Systems Biology at Harvard Medical School from 2010 to 2015. Prior to working at Merrimack, Dr. MacBeath served on the faculty in the Department of Chemistry and Chemical Biology at Harvard University from 2002 to 2010. Dr. MacBeath holds a B.S. in genetics from University of Manitoba, Canada and a Ph.D. in macromolecular and cellular structure and chemistry from The Scripps Research Institute in La Jolla, California.
Elizabeth Mansfield, Ph.D.
Deputy Office Director, Personalized Medicine and Molecular Genetics, Office of In Vitro Diagnostics and Radiological Health, CDRH, FDA

Dr. Mansfield is the Deputy Office Director for Personalized Medicine in the Office of In Vitro Diagnostics and Radiological Health (OIR) in the Center for Devices and Radiological Health (CDRH). Dr. Mansfield has extensive experience in regulation and policy regarding in vitro diagnostic devices, and has led the development of a personalized medicine program in CDRH. Dr. Mansfield received her Ph.D. from Johns Hopkins University, and completed postdoctoral training at NCI and NIAMS. She was the Director of Regulatory Affairs at Affymetrix, Inc. from 2004–2006.

Adam Margolin, Ph.D.
Director, Computational Biology, Associate Professor, Oregon Health & Science University

Adam Margolin is the Director of Computational Biology and an Associate Professor at Oregon Health Sciences University (OHSU). Dr. Margolin oversees the institution’s investments, strategic priorities and faculty recruitments in computational biology. Prior to joining OHSU, he worked as the Director of Computational Biology at Sage Bionetworks, a non-profit research organization that seeks to develop predictors of disease and accelerate health research. He has also worked as a staff scientist at the Broad Institute of Harvard and MIT, leading analysis projects to develop approaches to inform genotype-specific therapeutics.

Dr. Margolin is the founder and chair of the Global Alliance Genotypes-to-Phenotypes initiative. He also serves on the Bioassay Research Database External Advisory Committee and the DARPA Defense Science Office Advisory Committee on Med-Bio Data Analytics.

Dr. Margolin earned his bachelor’s degree in information systems and his master’s degree in computer science from the University of Pennsylvania. He received his Ph.D. in biomedical informatics from Columbia and completed his post doctorate at the Broad Institute.
Howard McLeod, Pharm.D.  
Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center

Dr. Howard McLeod is Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He is Chair of the Department of Individualized Cancer Management and a State of Florida Endowed Chair in Cancer Research. He is also a Senior Member of the Division of Population Sciences and Professor at the University of South Florida. Dr. McLeod is Chair of the NHGRI’s eMERGE Network External Scientific Panel and a recent member of the FDA Committee on Clinical Pharmacology and the NHGRI Advisory Council. Since 2002, Dr. McLeod has been Vice Chair for Pharmacogenomics for the NCI clinical trials group CALGB/ALLIANCE, overseeing the largest oncology pharmacogenomics portfolio in the world. Dr. McLeod is also a 1000 Talent Scholar of China and a Professor at Central South University in Changsha, China. Dr. McLeod is an active entrepreneur, serving on the board of directors, scientific advisory board and as a domain expert consultant to publically traded and privately held companies. He has also founded both for-profit and nonprofit companies in the U.S. and China. Howard has published over 500 peer-reviewed papers on pharmacogenomics, applied therapeutics and clinical pharmacology and continues to work to advance individualized medicine.

Amy M. Miller, Ph.D.  
Executive Vice President, Personalized Medicine Coalition

For nearly a decade, PMC Executive Vice President Amy M. Miller, Ph.D., has worked with innovators, scientists, providers and payers to reach consensus on policy issues impacting personalized medicine.

Before joining PMC, Miller worked in the Office of the Director of the National Institute of Mental Health, where she served as a liaison among the scientific community, the legislative branch, and the consumers of mental health care and their families. A former AAAS Fellow, she also served as a Domestic Policy Advisor to Senator Jay Rockefeller.

She began her career as a researcher at the National Institute of Child Health and Human Development. Miller received a B.A. from the University of New Orleans and holds a doctoral degree in human development from the University of Connecticut.
Lincoln Nadauld, M.D., Ph.D.
Executive Director, Precision Medicine and Precision Genomics, Intermountain Healthcare

Lincoln Nadauld is the Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare, an integrated health care system, where he oversees the clinical implementation of genomic cancer medicine across 22 hospitals and 180 physician clinics.

He is on the research faculty at Stanford University School of Medicine in the Division of Oncology focusing on cancer genomics and personalized cancer medicine. His work has been published extensively in journals such as *Nature Medicine*, *Journal of Clinical Oncology*, and *Genome Medicine*. He also serves on the Board of Directors of the Gastric Cancer Foundation, and regularly reviews grant applications on behalf of the Department of Defense. He also recently participated in the Precision Medicine Initiative Summit and roundtables at the White House with President Barack Obama.

Dr. Nadauld received a B.S. from Brigham Young University and a combined M.D./Ph.D. from the University of Utah. He completed clinical training in medical oncology at Stanford University School of Medicine, where he also completed a postdoctoral fellowship in solid tumor genomics, receiving the prestigious Young Investigator Award from the American Society of Clinical Oncology.

Daniel P. O’Day, M.B.A.
CEO, Roche Pharmaceuticals

Daniel O’Day is the CEO of Roche Pharmaceuticals, headquartered in Basel, Switzerland and with offices in more than 150 countries. Daniel was appointed to his current role in 2012, having previously been the head of the diagnostics division of Roche since 2010. Mr. O’Day acquired extensive commercial experience through diverse roles within Roche worldwide. These began at Roche Pharma in the U.S., where he held various commercial and sales roles between 1987 and 1998. Mr. O’Day then moved to the Roche Pharma headquarters in Switzerland, where he held leadership roles in Global Marketing and Lifecycle Management until 2001. Subsequently, he was Head of Corporate Planning at Roche Pharma in Tokyo, Japan between 2001 and 2003, General Manager at Roche Pharma in Denmark between 2003 and 2006, and President of Roche Molecular Diagnostics in California between 2006 and 2009.

Mr. O’Day obtained a Bachelor of Science in biology from Georgetown University, Washington, DC, in 1986 and an M.B.A. from Columbia University, New York, NY, in 1997.
Peter H. O’Donnell, M.D.
Assistant Professor of Medicine, Associate Director for Clinical Implementation, Center for Personalized Therapeutics, The University of Chicago

Peter H. O’Donnell is a translational researcher with advanced training in pharmacology and pharmacogenomics and a practicing oncologist specializing in the treatment of genitourinary malignancies, specifically bladder cancer.

His research interests focus on pharmacogenomics and clinical implementation of pharmacogenomic findings. Dr. O’Donnell serves as principal investigator of “The 1200 Patients Project,” a large clinical study exploring the feasibility and benefit of incorporating broad pharmacogenomic testing into routine clinical practice for patients with any type of disease.

Michael Panzara, M.D., M.P.H.
Head of Neurology Franchise, WAVE Life Sciences

Dr. Panzara is the Head of Neurology Franchise at WAVE Life Sciences, a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases.

Dr. Panzara has 15 years of biopharmaceutical industry experience developing therapies for neurological disorders. He served most recently as the Head of the Multiple Sclerosis, Neurology and Ophthalmology Therapeutic Area for Global Development at Sanofi Genzyme, where he was responsible for development strategy and oversight for compounds within these therapeutic areas. He joined Genzyme in 2009 as Group Vice President, Multiple Sclerosis and Immune Diseases, overseeing the development of Multiple Sclerosis (MS) and other inflammatory disease therapies, including the worldwide regulatory approvals of two MS drugs, Lemtrada (alemtuzumab) and Aubagio (teriflunomide). Prior to joining Genzyme, Dr. Panzara was Vice President, Chief Medical Officer, Neurology for Biogen.

Dr. Panzara received his undergraduate degree from the University of Pennsylvania and medical degree from Stanford University School of Medicine. He trained in neurology at Massachusetts General Hospital, received his post-doctoral training in immunology and rheumatology at Brigham and Women’s Hospital, and received his M.P.H. from the Harvard School of Public Health.
Dr. Pellini is the CEO and member of the Board of Directors of Foundation Medicine, a position he has held since joining the company in early 2011. Prior to Foundation Medicine, he was the President and Chief Operating Officer of Clarient, a GE Healthcare Company. Dr. Pellini joined GE Healthcare through the integration of Clarient, Inc., a national molecular diagnostics lab, where he worked to drive operational excellence and reimbursement strategies in parallel with the development and commercialization of multiple diagnostic tests.

Prior to his tenure with Clarient, Dr. Pellini served as Vice President, Life Sciences, at Safeguard Scientifics, Inc. and as Executive Vice President and Chief Operating Officer at Lakewood Pathology Associates, a national molecular pathology services company. He also previously served as Chief Executive Officer of Genomics Collaborative, Inc., a Boston-based biotech firm that was acquired by SeraCare Life Sciences, Inc. in 2004.

Dr. Pellini currently serves as a member of the Board of Directors for MassBIO and the Personalized Medicine Coalition, and on the President’s Advisory Board of the Kimmel Medical College of Thomas Jefferson University. He received a B.A. from Boston College, an M.B.A. from Drexel University and an M.D. from Thomas Jefferson University.

Anthony Philippakis is a physician, geneticist, and data scientist. He is currently a cardiologist at Brigham and Women’s Hospital, a venture partner at GV and the Chief Data Officer at Broad Institute of Harvard and MIT.

Anthony studied mathematics as an undergraduate at Yale University, followed by a master’s in mathematics at Cambridge University. He completed an M.D. at Harvard Medical School and a Ph.D. in biophysics at Harvard, working to develop computational methods for understanding transcriptional regulation. He completed his medical residency and cardiology fellowship at Brigham and Women’s Hospital.

Anthony is committed to bringing genome sequencing and data science into the practice of clinical medicine. As a clinician, he specializes in the care of patients with rare genetic cardiovascular diseases. He co-chairs the Scientific Advisory Board of Global Genes, is a strategic advisor to the American Heart Association and sits on the Clinical Working Group of the Global Alliance for Genomics and Health.
Lori M. Reilly, J.D.
Executive Vice President, Policy & Research, PhRMA

Lori M. Reilly is Executive Vice President for Policy and Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). Ms. Reilly leads PhRMA’s Policy and Research Department in the development and implementation of legislative, regulatory and political strategies to successfully navigate the ever-changing federal health care landscape, working to advance policies that encourage medical progress and patient access to the fruits of pharmaceutical innovation.

Ms. Reilly is a frequent presenter on biopharmaceutical industry-related issues, previously testifying before the House Energy and Commerce Subcommittee on Health regarding the reauthorization of the pediatric exclusivity program and the Food and Drug Administration Globalization Act. She also was Counsel at the U.S. House of Representatives Committee on Commerce and Chief of Staff/Counsel to House Ways and Means Committee member Representative Jon Christensen.

Ms. Reilly is a Member of the Virginia Bar and served on the Editorial Advisory Board of The Food and Drug Law Institute’s Policy Forum. She received a B.A. in political science from the University of Nebraska-Lincoln and a J.D. from the University of Nebraska College of Law.

Peer M. Schatz, M.B.A.
CEO, QIAGEN

Peer M. Schatz is Chief Executive Officer of QIAGEN and joined the company in 1993. He was previously a partner in a private management buyout group in Switzerland, worked in finance and systems positions at Sandoz AG and Computerland, and participated in the founding of start-up companies in the computer and software trading industry in Europe and the United States. Peer Schatz graduated from the University of St. Gallen, Switzerland, with a master’s degree in 1989 and obtained an M.B.A. in finance from the University of Chicago Graduate School of Business in 1991. He served as a member of the German Corporate Governance Commission from 2002 to 2012. He is a Board member of AdvaMedDx, a U.S. trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world, and ALDA (the Analytical, Life Science and Diagnostics Association), a trade association of developers and suppliers in these fields.
Michael S. Sherman, M.D., M.B.A.
Senior Vice President, Chief Medical Officer, Harvard Pilgrim Health Care

Dr. Michael Sherman serves as Chief Medical Officer and Senior Vice President for Harvard Pilgrim Health Care. He works with physicians and health care organizations to achieve sustainable improvements in cost and quality. He has focused the organization on introducing innovative, outcomes-based reimbursement models and developing outcomes-based payment agreements. Dr. Sherman is the Chair of the Board of Managers of the Harvard Pilgrim Health Care Institute, and also serves on the Advisory Board of the Institute for Clinical and Economic Review (ICER); the Board of Directors and as co-President of the Harvard Business School Healthcare Initiative; and the Board of Overseers for Boston’s Museum of Science.

Prior to joining Harvard Pilgrim, Dr. Sherman served as Corporate Medical Director, Physician Strategies, for Humana and held several leadership positions with UnitedHealth Group, Thomson Medstat (now IBM Truven), HealthAllies and Immusol.

Dr. Sherman holds a B.A. in anthropology and natural sciences and an M.S. in biomedical anthropology from the University of Pennsylvania. He received his M.D. from Yale and an M.B.A. from the Harvard Business School.

---

Greg Simon, J.D.
Executive Director, Cancer Moonshot Task Force

Greg Simon is the Executive Director of the Vice President’s Cancer Moonshot Task Force. Greg returns to the White House after serving as Vice President Al Gore’s Chief Domestic Policy Advisor between 1993 and 1997. Previously, Greg was the CEO of the financial firm Poliwogg Holdings and Senior Vice President of Worldwide Policy at Pfizer Inc. Prior to that, Greg was the founding President of FasterCures/The Center for Accelerating Medical Solutions, a center of the Milken Institute. He is also a former Board member of the Personalized Medicine Coalition. Greg received his B.A. in history from the University of Arkansas and his Juris Doctorate from the University of Washington, Seattle.
Meg Tirrell, M.S.J.
Reporter, CNBC

Meg Tirrell joined CNBC in April 2014 as a General Assignment Reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC’s Business Day programming, contributes to CNBC.com and is based at the network’s global headquarters in Englewood Cliffs, N.J.

Prior to joining CNBC, she led coverage of the biotechnology industry for Bloomberg News. She broke news on proxy fights, mergers and acquisitions, and drug development, and wrote features that illuminate how science and business meet. She also contributed to Bloomberg Television and Bloomberg Businessweek. She holds a master’s degree in journalism from Northwestern University and a bachelor’s degree in English and music from Wellesley College.

Alexander Vadas, Ph.D.
Managing Director, Partner, L.E.K. Consulting

Alexander Vadas, Ph.D., is a Managing Director and Partner in L.E.K. Consulting’s Biopharmaceuticals & Life Sciences practice. He joined L.E.K. in 2000 and focuses on diagnostics, research tools and personalized medicine. Within those areas, Dr. Vadas has worked with a range of established and emerging clients in the areas of corporate strategy, product strategy and planning and transaction support. Dr. Vadas received both his Bachelor of Science and Doctorate of Philosophy (Ph.D.) degrees in chemical engineering from the University of California, Los Angeles.
Barbara Weber, M.D.
Interim Chief Medical Officer,
Neon Therapeutics

Barbara has more than 25 years of experience in oncology research, in which time she has been widely published and received numerous academic and research awards for her work. Barbara joined Third Rock Ventures in 2015 and has spent the last six years at Novartis as Senior Vice President and Global Head of Oncology Translational Medicine. In this role, she was responsible for early clinical and translational scientific functions, including trial design and execution, implementation of patient selection strategies, and continuation of translational support through full development. Before joining Novartis, Barbara served as Vice President of three groups at GlaxoSmithKline, including Global Biomarkers, Oncology Discovery and Translational Medicine, and Cancer Metabolism Drug Discovery.

Barbara is a member of the American Association of Physicians and the American Society for Clinical Investigation, of which she served as President in 2005. Barbara has served on the Board of Directors of the American Society of Clinical Oncology and the American Association of Cancer Research. Barbara is a graduate of the University of Washington School of Medicine. She completed her residency in internal medicine at Yale University School of Medicine and her fellowship in medical oncology at the Dana-Farber Cancer Institute.

Edward Winnick
Editor-in-Chief, GenomeWeb

Edward Winnick is the Editor-in-Chief of GenomeWeb, an independent online news organization focused on the genomics research industry and the translation of that research into clinical practice. He has been at GenomeWeb for the past 12 years, serving as a reporter and editor covering the business, regulatory and policy issues affecting the genomics research and genetic testing industries. He assumed the role of Editor-in-Chief in March 2013 after running GenomeWeb’s Daily News operations for several years, and now also oversees 360Dx, GenomeWeb’s recently launched diagnostics-focused news site. Prior to joining GenomeWeb, Ed was Executive Editor of the Reuters Health Industry Briefing, where he led Reuters Health’s coverage of the pharmaceutical, biotech and health care industries. He began his journalism career in 1991 at Windhover Information, covering the diagnostics and managed care industries. Ed holds a B.A. from the University of Connecticut, in English and political science.
Janet Woodcock, M.D.
Director, Center for Drug Evaluation and Research, FDA

Janet Woodcock is Director of the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). As of January 2015, Dr. Woodcock also assumed the role of Acting Director of CDER’s newly formed Office of Pharmaceutical Quality (OPQ). Dr. Woodcock first joined CDER in 1994. For three years, from 2005 until 2008, she served FDA’s Commissioner, holding several positions, including Deputy Commissioner and Chief Medical Officer, Deputy Commissioner for Operations and Chief Operating Officer. Her responsibilities involved oversight of various aspects of scientific and medical regulatory operations. Before joining CDER, Dr. Woodcock served as Director, Office of Therapeutics Research and Review, and Acting Deputy Director in FDA’s Center for Biologics Evaluation and Research.

Dr. Woodcock received her M.D. from Northwestern Medical School and completed further training and held teaching appointments at the Pennsylvania State University and the University of California in San Francisco. She joined FDA in 1986.
The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system.
Organizing Committee

Edward Abrahams, Ph.D. (Chair)
President, Personalized Medicine Coalition

Amy Abernethy, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

Bonnie J. Addario
Founder, Chair, Bonnie J. Addario Lung Cancer Foundation; Founder, Addario Lung Cancer Medical Institute

Jennifer Cosenza
Senior Vice President, Feinstein Kean Healthcare

William S. Dalton, Ph.D., M.D.
CEO, M2Gen; Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center; Board Chairman, Personalized Medicine Coalition

George Demetri, M.D.
Director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute

Stephen L. Eck, M.D., Ph.D.
Vice President, Oncology Medical Sciences, Astellas Pharma Global Development

Margaret Foti, Ph.D., M.D. (h.c.)
CEO, American Association for Cancer Research

Pia Gargiulo, Ph.D.
Founder, Wild Type Advisors

Kathy Giusti, M.B.A.
Founder, Executive Chairman, Multiple Myeloma Research Foundation

Robert C. Green, M.D., M.P.H.
Associate Physician, Brigham and Women’s Hospital, Associate Professor of Medicine, Harvard Medical School, Geneticist, Brigham and Women’s Hospital, Director, Genomes2People Research Program

Richard Hamermesh, D.B.A.
Faculty Co-Chair, Kraft Precision Medicine Accelerator, Senior Fellow, Former MBA Class of 1961, Professor of Management Practice, Harvard Business School

Trevor Hawkins, Ph.D.
Enterprise-in-Residence, GE Ventures

Robert Huckman, Ph.D.
Albert J. Weatherhead III Professor of Business Administration, Faculty Co-Chair, Health Care Initiative, Harvard Business School

Patrick James, M.D.
Senior Managing Director, Quest Diagnostics

Katherine Johansen Taber, Ph.D.
Director, Personalized Medicine, American Medical Association

Marcia A. Kean, M.B.A.
Chairman, Strategic Initiatives, Feinstein Kean Healthcare

Michael Kolodziej, M.D.
National Medical Director, Managed Care Strategy, Flatiron Health

Jeffrey A. Leerink
Founder, Chairman, CEO, Leerink Partners

Mark Levin
Partner, Third Rock Ventures

Amy M. Miller, Ph.D.
Executive Vice President, Personalized Medicine Coalition

Tom Miller
Founder, Managing Partner, GreyBird Ventures

Cynthia Casson Morton, Ph.D.
William Lambert Richardson Professor of Obstetrics, Gynecology and Reproductive Biology, Professor of Pathology, Harvard Medical School; Director of Cytogenetics, Brigham and Women’s Hospital

Michael Pellini, M.D.
CEO, Foundation Medicine

Kimberly Popovits
Chairman, Chief Executive Officer, President, Genomic Health
We believe in more than the big breakthroughs. And more than the next big thing.

We believe in the day-in day-out work of making science happen. And the millions of little victories – and failures – in between the breakthroughs. Because to us, it’s the daily effort of everyday people that changes the future. So we don’t stop. We keep working. Every day.
The cobas® EGFR Mutation Test v2 is the first and only companion diagnostic test to receive FDA approval to use a liquid biopsy specimen for testing of patients with non-small cell lung cancer (NSCLC). The test can use plasma or tumor tissue samples to identify patients who are likely to benefit from treatment with Tarceva® (erlotinib) or TAGRISSO™ (osimertinib). The plasma option offers physicians a way to make testing more accessible by using a simple blood draw instead of a surgical biopsy to obtain a suitable sample.

With flexible sample requirement, clinically proven broad and sensitive mutation coverage, and speed to result, the cobas® EGFR Mutation Test v2 removes barriers to testing and gives physicians the information needed to make confident treatment decisions for their critically ill patients.

Talk to your Roche representative or visit www.cobasEGFRtest.com for more information.

COBAS® EGFR MUTATION TEST V2
The only FDA-approved test to use plasma to detect EGFR mutations in NSCLC patients

Connecting the Ecosystem of Life Science Innovators
FKH has worked at the forefront of every wave of technology adoption in life sciences and healthcare for the past 30 years.

In collaboration with today’s innovators, we have pioneered a novel blend of business strategy, policy and communications consulting services to shape the future of biomedicine.

Learn more at www.fkhealth.com

Feinstein Kean Healthcare

The firm worth listening to
is the firm that listens to you.
Talk to Foley. We’re listening.

Our clients ask for insight to guide them through the processes that minimize risk and create sustainable business solutions. Our Personalized Medicine attorneys offer experience in private equity, privacy, reimbursement, and IP to help you advance your business.

Tell us how Foley can add value to your business.
Contact Partner Antoinette Korsiak in our Silicon Valley office at akorsiak@foley.com.
The largest real-world oncology clinical data source

Flatiron Health delivers research-grade, real-world clinical data from the EHR that is unparalleled in scale, recency, and depth.

Now we’re unlocking the full view of the patient journey by integrating clinical outcomes and genomic data into the Clinico-Genomic Registry, in partnership with Foundation Medicine.

Before it became a medicine,

It was 5,000 researched compounds.
87 different protein structures.
500,000 lab tests.
1,600 scientists.
80-hour workweeks.
14 years of breakthroughs and setbacks.
36 clinical trials.
8,500 patient volunteers.
And more problems to solve than we could count.

Before it became a medicine,

It was an idea in the mind of a Pfizer scientist.

Now it’s a medicine

That saves lives every day.

Oracle Health Sciences solutions—built by healthcare professionals for healthcare professionals

Oracle’s comprehensive healthcare solutions create a fast-growing, best-of-breed ecosystem for managing both clinical and genomic data to deliver a new standard of care from individuals to populations.

For more information, visit www.oracle.com/goto/precisionmedicine

© Copyright Pfizer Inc. All Rights Reserved.
Attacking cancer is now personal.

We’ve developed new technology and processes to better fight advanced cancers. Using a revolutionary method of gene sequencing, our experts now deliver more precise medicine than ever before. We’re providing these treatments to patients across the nation, giving more people a better quality of life.

435.251.5780 • genomics@imail.org
For more information or to order a test, visit precisioncancer.org
At Astellas, we believe we can make a real impact on the future.

That’s why we are fully committed to developing medicines that make a difference where they’re needed most, in areas like oncology, urology, cardiology and transplant. It’s also why we focus on bringing together a diverse group of people with a common goal: to help transform lives. Whether it’s in the office, the laboratory or the community, we’re working together to change tomorrow.
It is much more important to know what sort of a patient has a disease than what sort of a disease a patient has.
- Sir William Osler, M.D. (1849-1919)

The Precision Medicine Alliance salutes the Personalized Medicine Coalition on their work to bring the promise of advanced patient knowledge to benefit our communities.

REGISTER NOW

Please join us for this one-day, one-of-a-kind thought leadership forum to discuss the critical business issues and opportunities surrounding the advancement of personalized medicine, including the importance of collaboration across industry stakeholders. Plus, network with key decision makers and peers from life sciences companies, health care providers, financial entities, and research and policy organizations.

FEATURED TOPICS TO INCLUDE:
- PAYMENT
- BIG DATA
- FDA REGULATORY
- CLINICAL ADOPTION
- DISRUPTIVE INNOVATION
- BIG PHARMA
- INTELLECTUAL PROPERTY
- FINANCING AND VENTURE CAPITAL

Personalized Medicine Conference attendees save 40% off the regular Corporate/Professional Services registration rates.
Enter discount code PMConfVIP when registering online at personalizedmedicinesummit.com.
BREAKING NEWS
AT YOUR FINGERTIPS

Stay Informed with the latest personalized medicine headlines from the gw newsroom

GenomeWeb's newsroom delivers in-depth, real-time reporting on the biggest stories in life science and molecular diagnostics.

DNA SEQUENCING
MOLECULAR DIAGNOSTICS
GENETIC TESTING
CANCER GENOMICS
INFECTIOUS DISEASE
PCR

REGISTER TODAY for our FREE Daily News bulletin
www.genomeweb.com
There’s no better place to connect with biotech’s top people and most innovative technologies than at BIO 2017. You’ll experience powerful business partnering, benefit from invaluable personalized medicine education sessions and have the chance to network with over 15,000 of the industry’s best and brightest.
SAVE THE DATE

13th Annual Personalized Medicine Conference

November 14–16, 2017